With some help from there humans, Houston pets can get virtual care through a Texas startup. Image courtesy of TeleVet

A Texas-based, digitally optimized company focused on veterinary care is helping pet owners connect with medical professionals from the comfort of their homes, offsetting the impact of the social distancing measures to reduce the spread of COVID-19.

TeleVet Inc., which is based in Austin but is used by local veterinarians, recently announced that they will be providing their animal telemedicine platform free for one month to provide essential animal healthcare, connecting animal patients to veterinarians all over the country. TeleVet is used across 1,000 clinics and is accessible on phone, tablet, or computer.

The free month will be provided to cities that have been hard-hit by the virus such as New York City, Atlanta, New Orleans, San Francisco, Seattle, Miami, Las Vegas, and Chicago.

"In some cases, clinics in impacted cities are having to suddenly shut down or doing drop off visits," Steven Carter, co-founder, and CEO of TeleVet, tells InnovationMap. "We see that telemedicine is a huge component to keeping their staff and their client base during a time when social distancing is critical to flattening the curve of coronavirus cases."

Houston-area vet Amy Garrou and the other vets in her practice have been using TeleVet for several months before the outbreak of the virus. Before the platform, animal patients and their owners had to come into the office for post-surgery check-ups or other outpatient procedures. Garrou says her practice has been increasing the number of patients who use the platform since before the social distancing measures, making it a part of their daily workflow.

"We can check for infections such as ear infections or drainage from either a still picture or a video, or even a live video conference with the owner," says Garrou. "The platform has been useful because we can do any of those consultations and get the information we need to manage the case without the pet owner having to come into the clinic."

In January, TeleVet closed a $2 million seed round with investments from Houston-based Mercury Fund and Nebraska-based Dundee Venture Capital. (Amy Garrou is the wife of Mercury Fund Managing Director Blair Garrou.) According to the company's LinkedIn page, TeleVet is hiring.

Since being founded in 2015, the company has become a U.S. market leader in animal telemedicine. Over the last few years, telemedicine has been quickly expanding, and during the coronavirus outbreak, there has been a greater rush to move towards providing telemedicine for humans as well as pets.

"We realized that a lot of stuff can be solved remotely, keeping the client and the pet at home so that the staff does not have to physically interact with the client which offers convenience to both the client and the vet," says Carter.

Vets like Garrou say TeleVet helps them streamline the process by syncing with their medical records software seamlessly. This cuts costs and saves time from administrative duties. This also allows pet-owners to have access to medical notes regarding the health of their pet.

Her office is thinking of offering a curbside pick up service where they use TeleVet to communicate with pet owners to provide a contactless vet visit. A medical professional with personal protection equipment meets them in the parking lot and escorts the pet inside the vet's office where they use live video feed during the consultation so the owner can continue to be part of the process.

"It's proved to be really vital, especially in those cities where there's a complete shutdown," says Garrou. "The number of people that are realizing they've got to do something in this environment to keep their businesses afloat is rising."

As reliance on telemedicine increases due to the crisis, Garrou says it will eventually become part of the options available for pet owners, and especially vets who work long hours and tend to suffer from high levels of stress and burnout.

"We're really focused on helping, not only just to keep vets' businesses afloat right now," says Carter. "We can't stress enough that we care about the individuals in those practices. We want to help vets with work-life balance and reduce the burnout rate."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.